LCG
LRMR icon

Lisanti Capital Growth’s Larimar Therapeutics LRMR Stock Holding History

Lisanti Capital Growth’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,976
Closed -$939K – 97
2015
Q1 		$939K Sell
1,976
-2,731
-58% -$1.3M 0.54% 83
2014
Q4 		$1.74M Buy
4,707
+471
+11% +$121K 0.87% 59
2014
Q3 		$999K Buy
+4,236
New +$960K 0.5% 80

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Lisanti Capital Growth's LRMR Position: Q2 2015 in Review

Lisanti Capital Growth sold out of Larimar Therapeutics (LRMR) in Q2 2015, closing a stake of 1,976 shares — an estimated $939K sold.

Lisanti Capital Growth first reported a position in LRMR in Q3 2014 and held it in 3 quarters. The position peaked at $1.74M in Q4 2014. 89 funds tracked by Wall St. Rank hold LRMR as of Q2 2015.

  • Lisanti Capital Growth reported no remaining Larimar Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Lisanti Capital Growth sold 1,976 Larimar Therapeutics shares in Q2 2015, an estimated $939K.
  • Lisanti Capital Growth first reported a position in Larimar Therapeutics in Q3 2014 and held it in 3 quarters.
  • Lisanti Capital Growth's Larimar Therapeutics position peaked at $1.74M in Q4 2014.
  • 89 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2015.

Based on Lisanti Capital Growth's 13F filing for Q2 2015, filed 24 Jul 2015.